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Abstract: Future therapeutic intervention that could effectively decelerate the rate of 
degeneration within the substantia nigra pars compacta (SNc) could add years of mobility 
and reduce morbidity associated with Parkinson’s disease (PD). Neurodegenerative decline 
associated with PD is distinguished by extensive damage to SNc dopaminergic (DAergic) 
neurons and decay of the striatal tract. While genetic mutations or environmental toxins 
can precipitate pathology, progressive degenerative succession involves a gradual decline 
in DA neurotransmission/synaptic uptake, impaired oxidative glucose consumption, a rise 
in striatal lactate and chronic inflammation. Nutraceuticals play a fundamental role in 
energy metabolism and signaling transduction pathways that control neurotransmission and 
inflammation. However, the use of nutritional supplements to slow the progression of PD 
has met with considerable challenge and has thus far proven unsuccessful. This review  
re-examines precipitating factors and insults involved in PD and how nutraceuticals can 
affect each of these biological targets. Discussed are disease dynamics (Sections 1 and 2) 
and natural substances, vitamins and minerals that could impact disease processes 
(Section  3). Topics include nutritional influences on α-synuclein aggregation, ubiquitin 
proteasome function, mTOR signaling/lysosomal-autophagy, energy failure, faulty 
catecholamine trafficking, DA oxidation, synthesis of toxic DA-quinones, o-semiquinones, 
benzothiazolines, hyperhomocyseinemia, methylation, inflammation and irreversible 
oxidation of neuromelanin. In summary, it is clear that future research will be required to 
consider the multi-faceted nature of this disease and re-examine how and why the use of 
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nutritional multi-vitamin-mineral and plant-based combinations could be used to slow the 
progression of PD, if possible.  
Keywords: Parkinson’s disease; neuroprotective; neuromelanin; nutrition; vitamins 
Abbreviations:  
6-OHDA  6 Hydroxydopamine  mRNA   Messenger ribonucleic acid 
AADC   Aromatic amino acid 
decarboxylase 
mTOR  Mammalian target of 
rapamycin 
AMPA   α-amino-3-hydroxyl-5-methyl-
4-isoxazole-propionate 
NA Nucleus  accumbens, 
AP-1   Activator protein 1  NAC   N acetyl L cysteine 
ATP   Adenosine triphosphate  NAD
+   Nicotinamide adenine 
dinucleotide 
BBB   Blood brain barrier  NADH   Nicotinamide adenine 
dinucleotide reduced 
CBF  Cerebral blood flow  NADPH   Nicotinamide adenine 
dinucleotide phosphate reduced 
CMRG  Cerebral metabolic rate of 
glucose 
NF-κB  Nuclear factor-kappa B  
CMRG   Cerebral metabolic rate of 
glucose 
NM   Neuromelanin 
COMT   Catechol-O-methyltransferase NMDA    N-methyl-D-aspartate 
COX   Cyclooxygenase  NNMT   Nicotinamide N-methyl 
transferase 
CSF   Cerebral spinal fluid  NOS   Nitric oxide synthase 
DA   Dopamine  NT   Neurotransmitter 
DAergic   Dopaminergic  O2
− Superoxide 
DAT   Dopamine transporter  OXPHOS  Oxidative Phosphorylation 
DOPAC   3,4-dihydroxyphenylacetic acid  PARP-1   Poly [ADP-ribose] polymerase 1 
DTBZ  
[11C]-dihydrotetrabenazine  PD   Parkinson’s disease 
ERK   Extracellular signal-regulated 
kinases 
PDE   Phosphodiesterase 
FAD   Flavin adenine dinucleotide  PDPC   Plant derived polyphenolic 
compounds 
FD  
[18F]-fluoro-l dopa  PET  Positron emission tomography 
FDG  
[18F]-Fluoro-deoxyglucose  PGE2   Prostaglandin E2 
FMN   Flavin mononucleotide  PGH2   Prostaglandin H2 synthase 
GABA   Γ-Aminobutyric acid  PI3K   Phosphoinositide 3 kinase 
GSHPx   Glutathione peroxidase  PINK-1   PTEN-induced putative kinase 1 
GSH   Reduced Glutathione  PK   Pyruvate kinase 
H2O2   Hydrogen Peroxide  PLA2   Phospholipase A2 
HO-1   Heme oxygenase 1  PPO   Polyphenol Oxidase 
HVA   Homovanillic acid  PY   Pyruvate 
IKK   I kappaB kinase  ROS   Reactive Oxygen Species 
IL   Interleukin  Se   Selenium 
INOS   Inducible NOS  SLP  Substrate level phosphorylation Int. J. Mol. Sci. 2011, 12                 
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JNK   c-jun N-terminal kinase  SN   Substantia nigra 
LC   Locus coeruleus  SNc   Substantia nigra pars compacta 
LDH   Lactate Dehydrogenase  SNCA   α-synuclein 
l-DOPA   l-3,4-dihydroxyphenylalanine   SOD   Superoxide dismutase 
LOX   Lipoxygenase  SPECT   Single photon emission 
computed tomography 
MAO   Monoamine oxidase  TH   Tyrosine hydroxylase 
MAPK   Mitogen-activated protein 
kinase 
TNF   Tumor necrosis factor 
MP  
11C-methylphenidate UPS  Ubiquitin-proteasome  system 
MPP
+   1-methyl-4-phenylpyridinium  VMAT2   Type-2-vesicular monoamine 
transporter 
MPTP   1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine 
Zn   Zinc 
 
1. Introduction 
1.1. Pathology 
The pathology of Parkinson’s disease (PD) involves chronic degeneration of dopaminergic 
(DAergic) neurons in the substantia nigra pars compacta (SNc). Subsequent decay of the nigrostriatal 
tract manifests itself clinically by symptomatic rigidity, bradykinesia, postural instability and resting 
tremor. Prominent pathological manifestations associated with degeneration of SNc DAergic   
neurons include observations describing mitochondrial abnormalities [1–4], excessive cytosolic 
dopamine (DA) oxidation, α-synuclein aggregates, autophagolysosome dysfunction, defects in the   
ubiquitin-proteasome system (UPS), oxidative stress, nitrosative stress, iron released from bound 
storage and a gradual loss of neuromelanin (NM) [5–7]. These pathological insults are self reinforcing 
and can advance in cyclical fashion, often intensified by decaying levels of glutathione (GSH), which 
render greater oxidative damage (via O2, H2O2, OH) [8,9] or lipid/protein nitration (via ONOO
−) and 
accumulation of 3-nitrotyrosine, protein carbonyls, 8-hydroxyguanosine, malondialdehyde and 
hydroxynonenol in degenerating neurons [10–12]. Neurological degeneration can also be aggravated 
by chronic central nervous system (CNS) inflammation which can involve recruitment of activated 
microglial cells, release of cytotoxic molecules, free radicals and glutamate, which can provoke 
neuritic beading, excitotoxic, apoptotic and necrotic degeneration [13]. While gradual loss of DAergic 
SNc pigmented cells occur as a natural process of aging—early diagnosis of PD is associated with a 
30%/60% reduction of DAergic neurons/striatal DA which is attributable to degeneration of striatal 
axon terminals [14]. Though the etiology circumscribing the selective loss of SNc DAergic neurons in 
PD is not fully understood, we do know that reportedly ~5–10% of PD patients display mutations  
in genes such as DJ-1, PTEN-induced kinase 1 (PINK-I), leucine-rich repeat kinase 2 (LRRK2)   
G2019S, park-1/Synuclein (SNCA), ubiquitin-carboxy-terminal-hydrolase L1, parkin (Del3-5, T240R,  
Q311X) [15–18], ATP13A2 (Park 9), β-glucocerebrosidase and mitochondrial proteins such as park 
13 Omi/Htra2, Complex I [19–22]. The larger majority of PD cases result from a fusion of natural Int. J. Mol. Sci. 2011, 12                 
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aging and/or environmental exposures to pesticides, a history of depression, viral/bacterial infections, 
metals, antipsychotic/antidepressant drugs, rural/farm living or lack of habitual cigarette 
smoking/tobacco use or consumption of caffeine [23–27]. All of these studies provide partial insight as 
to the precipitating factors involved with PD onset and progression. Moreover, the greatest commonality 
appears to be either genetic mutations or environmental triggers that lead to direct/indirect 
accumulation of malfunctional mitochondria, which precede selective DAergic SNc degeneration. 
The extent of DAergic SNc losses in human PD can be imaged using positron emission tomography 
(PET) or single photon emission computerized tomography (SPECT). Radioactive tracers in PD 
patients have been used to substantiate (1)  compromised integrity of pre-synpatic nigrostriatal 
projections,  i.e., 
[18F]LDOPA (which monitors DA uptake, metabolism, DOPA decarbarboxylase 
(DDC), DA storage within intact nerve terminals); (2)  faulty DA transporters  
(DAT)  i.e., CFT, C-RTI-32, FP-CIT ligands, 
[11C]methylphenidate (MP)/99mTc-TRODAT-1 or   
(3)  abnormal type-2-vesicular monoamine transporter (VMAT2) function using tracers such as   
[11C]-dihydrotetrabenazine (DTBZ) which measures cytoplastic DA uptake into synaptic vesicles [28–30]. 
Chronic SNc DAergic degeneration parallels a reduction of 
[18]F-DOPA uptake and DAT binding 
which are foundational events to faulty circuitry in the basal ganglia that ultimately triggers 
locomotive disability [31].  
Figure 1. PET Imaging Tools Used in PD. Schematic representation of dopamine synthesis 
and metabolism, including sites of action of pre-synaptic dopaminergic PET ligands.   
(1) FD reflects uptake of l-dopa, the AADC activity, and the storage of dopamine in   
pre-synaptic vesicles; (2) MP binds to the dopamine transporter, which is specific   
for the gradient-determined re-uptake of dopamine; and (3) DTBZ binds to vesicular 
monoamine transporter type 2, which is responsible for the uptake of monoamines   
into pre-synaptic vesicles. In the striatum, more than 95% of the monoaminergic   
nerve terminals are dopaminergic. (AADC: aromatic amino acid decarboxylase;   
COMT: catechol-O-methyltransferase; DOPAC: 3,4-dihydroxyphenylacetic acid;   
DTBZ: 
[11C]-dihydrotetrabenazine; FD: 6-
[18F]-fluoro-ldopa; HVA: homovanillic acid;   
l-DOPA: l-3,4-dihydroxyphenylalanine; MAO: monoamine oxidase; MP: 
[11C]-d-threo-
methylphenidate; 3-MT: 3- methoxytyramine; TH: tyrosine hydroxylase) [30]. 
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Figure 2. Imaging dopamine terminal function in healthy controls and early Parkinson’s 
disease (Modified from [28]). 
 
1.2. Treatment  
In order to counteract the loss of SNc DAergic neurons, medical treatments are aimed at modulating 
neurotransmitter (NT) function. Prescription medicines allow for fluid voluntary movement,   
reduction of tremors and a sustained quality of life. Routine adjunct therapies often combine 
levodopa/dopa-decarboxylase inhibitors Sinemet
® and Madopar
® with DA receptor agonists,   
catechol-o-methyltransferase inhibitors, monoamine oxidase (MAO) inhibitors, anti-cholinergics and 
surgical treatments [32]. While prescription drugs ameliorate the symptoms, they do not necessarily 
address the central etiology of degeneration and therefore a number of alternative approaches have 
been considered to slow the progression of this disease. 
1.3. Previous Studies on Therapeutic Agents to Slow Progression of PD  
Innovative strategies to slow the progression have met with partial success in experimental models, 
and to a less significant extent in clinical trials. Most neuroprotective strategies seem to fall under the 
general classes of anti-inflammatory, anti-apoptotic, anti-oxidants, enzyme inhibitors, growth factors, 
alternative medicine or receptor antagonists/agonists. Experimental trials elucidating efficacy of 
neuroprotective agents are rapidly expanding, and have thus far included superoxide dismutase 
(SOD)/catalase/peroxidase mimetics [33], anti-apoptotic MAO inhibitors, rasagiline [34–38],   
(−)-epigallocatechin-3-gallate, iron chelator/antioxidant/anti-inflammatory combinations [39–41], 
celastrol, nitric oxide synthase (NOS) inhibitors [42,43], COX, c-jun N-terminal kinase (JNK) 
inhibitors [44–47], alpha-tocopherol, coenzyme Q10, lipoic acid [48–52], creatine [53,54]   
melatonin, catalpol from root of Rehmannia glutinosa Libosch [55,56], N-acetyl-L-cysteine (NAC),  
thiol antioxidants [57], nerve growth factors [58,59], dehydroepiandrosterone [60], estrogen   
receptor agonists [61], adenosine A2 receptor antagonists [62–68], S-allylcysteine [66],   
mGlu2/3 metabotropic [67], acupuncture [68] traditional Chinese medicine Zhen-Wu-Tang [69]   Int. J. Mol. Sci. 2011, 12                 
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angiotensin-converting enzyme inhibitors [70], nicotine, ginseng, ginkgo biloba, caffeine   
and cannabis [71].  
Despite the success using a vast range of therapeutic agents in preliminary experiments, there is a 
general failure of clinical trials to substantiate therapeutic effects that slow disease progression, in 
particular for antioxidants. This may be attributable to limitations in the current animal or in vitro 
models that make extrapolation of information for human PD difficult. Further, the pathology is very 
complex and may not be effectively antagonized with just single therapy antioxidant, ergogenic,   
anti-inflammatory regimens. 
The use of nutritional supplements to slow the progression of PD has also not been fully 
substantiated by evidenced-based studies. The aim of this review is to re-visit the pathology of PD, and 
in light of pathological processes further discuss the rationale behind potential use of vitamin/mineral 
nutraceutical neuroprotective agents. In this review, the details of pathology are presented in 
Sections  1  and  2, and further discussed relevant to nutrient interactions in Section 3. Discussion 
includes the role of vitamins and minerals in the established United States recommended daily 
allowances, as well as macronutrients and plant based constituents that modulate processes with 
specific relevance to PD. The review is a combination of past literature and proposed theory based on 
known molecules that affect known biological targets which range from mitochondrial malfunction, 
inflammation, DA oxidation and defective UPS/lysosomal autophagy processes. Moreover, some of 
the compounds proposed in this review have not yet been evaluated. 
2. Review  
2.1. Energy Failure—Loss of OXPHOS, Rise in Anaerobic Glycolysis & Lactate, ATP Depletion 
We first review the most prominent issue underlying the loss of DAergic neurons, which is a 
fundamental failure in glucose metabolism due to aberration of mitochondrial respiration. It is 
important to note that mitochondrial malfunction could initially occur due to toxic effects of   
α-synuclein, endogenous neurotoxins or exogenous environmental factors. However, experimental 
models often employ use of mitochondrial toxins such as 1-methyl-4-phenylpyridinium (MPP
+), 
rotenone or endogenous isoquinolines to selectively target neuropathological damage similar to, but 
not identical to PD degenerative effects mainly in the SNc and the locus coeruelus (LC) [72–74].  
Loss of mitochondrial function leads to immediate failure of DA neurotransmission and 
acceleration of glycolysis to overcome the loss of oxidative phosphorylation (OXPHOS) through 
substrate level phosphorylation (SLP) [75–77]. The impact of mitochondrial toxins on these energy 
processes is almost always observed. In vivo, administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) generates an immediate rise in glucose utilization (detected with   
[2-14C]deoxyglucose), a drop in ATP, a rise in lactate production, reduction in striatal DAT/DA and loss 
of tyrosine hydroxylase immunoreactivity, effects which are exacerbated by -synuclein [78–83]. The 
drop in ATP suggests that energy deficiency is clearly involved with the process of initiating 
degenerative decline [84]. Moreover, there is ample information to substantiate that a drop in energy 
corresponds to a rise in glycolysis to drive SLP, an indicator of metabolic stress. The use of proton 
magnetic resonance spectroscopy (1H-MRS) has been used to confirm sharp spikes in striatal lactate, 
which occur within 2 h of MPTP injection in C57BL/6 mice [85]. In primates, a long term study Int. J. Mol. Sci. 2011, 12                 
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utilizing infusion of MPTP over 14 ± 5 months resulted in loss of DA pre-synaptic re-uptake, parallel 
to a 23-fold increase in striatal lactate production, which was sustained for up to 10 months post final 
administration of MPTP [86]. While the CNS is most often studied with respect to biochemical effects 
induced by systemic injection of MPTP, damage in peripheral tissue such as skeletal muscle   
also involves heightened anaerobic glycolytic function, elevation of lactic acid dehydrogenase   
and concomitant decrease of mitochondrial Complex IV, with no changes in mitochondrial 
Complex I [87]. These shifts toward anaerobic metabolism occur in tissues with capability to uptake 
MPP
+ where similar patterns observed include loss of ATP, loss of OXPHOS, a rise in glycolysis, 
heightened production in lactate and neurotoxic effects which can be blocked by providing abundant 
glucose to growth media in order to sustain ATP production through glycolysis [77,88–93]. The 
reliance of damaged neurons on greater anaerobic glycolytic function is not exclusive to PD, as head 
trauma, seizure or ischemia can equally provoke a rise in brain/CSF lactate and loss of ATP parallel  
to neurological damages [94–98]. In Section 3, we discuss nutrients involved with propelling   
anaerobic function. 
In the human brain, in vivo functional imaging strategies to assess glucose metabolism in the brain 
include PET with a 
[18F]2-fluoro-2-deoxy-D-glucose (
[18F]FDG) tracer. This tracer is used to quantify 
elevated rates of glycolysis/glucose transport relative to surrounding tissue. Some limitations for this 
method involve the non-specific manner by which 
[18F]FDG accumulates in the brain. 
[18F]FDG enters 
through the glycolytic cycle prior to conversion of pyruvate, therefore its measurement does not 
differentiate between aerobic (OXPHOS) and anaerobic (SLP) metabolism. Further, uptake is not 
selective to cell type and therefore false positives (or heightened metabolic activities) are likely to 
occur in particular for diseases involving active inflammatory tissue, where metabolic rate of glucose 
is extremely high [99]. This technique however, has been used in sliced striatal tissue to corroborate 
that regional exposure to MPP
+ can evokes a sharp rise in cerebral glucose metabolic rate 
(CMRglc)  [93]. FDG PET studies could also be beneficial in terms of evaluating patterns in   
non-diseased, non-inflammatory models. FDG PET imaging techniques clearly show that the process 
of aging in monkeys, corresponds to loss in both regional cerebral blood flow/
[15O] H2O and rCMRglc 
in many areas of the brain including the cerebellum, hippocampus, striatum, occipital cortex, temporal 
cortex, and frontal cortex [100]. Age associated hypometabolism in the human brain is also believed to 
precipitate increased risk for many age associated CNS neurodegenerative diseases [101]. Future 
research is now considering preventative implementation with nutrients that could assist in minimizing 
metabolic losses [101].  
In brief, the loss of ATP in the SNc is detrimental because this single event can initiate a range of 
downstream collapse on energy requiring systems that can then lead to (1) catecholamine oxidation 
and formation of DA neurotoxins/free radicals (2) excitotoxic and programmed cell death   
(3) mitochondrial transition pore opening, matrix swelling, release of mitochondrial proteins into the 
cytosol, apoptosis [102–107] and microtubular/cell structure collapse [108].  
2.2. Loss of DA Regulation and Trafficking—VMAT2 
One of the first events brought about by reduction of ATP is a loss of energy requiring systems that 
drive DA trafficking. Section 3, also refers to a large number of nutraceuticals that can block these Int. J. Mol. Sci. 2011, 12                 
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processes. Failure of DA trafficking, not only occurs due to decline in ATP, but can also result from 
genetic mutations in SNCA (A53T and A30P) [109], mitochondrial insufficiency or oxidative damage 
by ROS, all which trigger excessive DA release from SNc nerve terminals [110,111]. With regards to 
energy, a lack of ATP diminishes the capability of intracellular ATPase pumps to sequester DA into 
synaptic vesicles (where DA is stable due to slightly acidic pH), which is a pivotal factor in initiating a 
cascade of neurotoxic events [112,113]. Failure of vesicle monoamine transporter 2 (VMAT2) results 
in immediate leaked DA into the cytosolic compartment (easily subject to oxidative breakdown at 
neutral pH) where it readily oxidizes to form neurotoxic DA-quinones, o-semiquinones, dopaminergic 
poisons and related free radicals [114–116] which can then contribute to eventual decay of the   
striatal tract [117].  
Further, functional loss of VMAT2 can occur due to age-associated losses in VMAT2 mRNA 
expression, which create vulnerability to extensive neurological damage in the presence of 
mitochondrial toxins such as MPTP in vivo or MPP
+ in vitro [118–123]. MPP
+ can cause further insult 
due to its ability to bind directly to VMAT2, gain entrance into synaptic vesicles and initiate extrusion 
of DA back into the cytoplasmic compartment [124,125].  
2.3. Dopamine Oxidation 
Inadequate function or expression of VMAT2 mRNA has also been reported in association with 
PD  [126], which could precipitate three main routes by which the oxidation of DA can become 
pathological. These include (1) the enzymatic oxidation of DA via tyrosinase, phospholipase A2 
(PLA2)/prostaglandin H synthase (COX), lipoxygenase and xanthine oxidase to form DA-quinone en 
route to neuromelanin synthesis (2) non-enzymatic autoxidation of DA by the presence of oxygen, 
H2O2, or metals and (3) the enzymatic oxidation of DA by MAO which can lead to H2O2 production 
and synthesis of DA-aldehydes. The heavy oxidation of DA (be it non-enzymatic or enzymatic) seems 
to initiate neurodegenerative pathogenesis, a depletion of glutathione, oxidation of available ascorbate 
and subsequent oxidative stress in the SNc area [127]. In Section 3, we provide information on 
nutraceuticals that may be able to antagonize each of the major routes of DA oxidation. 
2.3.1. Enzymatic Oxidation of DA, the Neuromelanin Pathway & DA-Quinones 
Understanding the role of target enzymes and how they exacerbate DA oxidation could be 
beneficial in directing future investigation or design of nutraceutical combinations. First, the 
enzymatic oxidation of DA occurs through heightened activity of tyrosinase, COX, lipoxygenase and 
xanthine oxidase which converts DA to DA-quinone en route to neuromelanin (NM) [128]. The 
neuromelanin pathway if intensified can produce deleterious DA-quinone neurotoxic metabolites such 
as o-semiquinones or benzothiazolines, which are potent inhibitors of mitochondrial pyruvate 
dehydrogenase (i.e., complex I/Krebs cycle) and initiators of -synuclein fibrillization [129–132]. 
Oxidized DA can further react with thiols producing DA-cysteine adducts such as 5-S-cysteinyldopamine 
which mediate metal catalyzed oxidation of proteins, which lead to protein misfolding and   
aggregation [131]. While gradual accumulation of NM in SNc tissue occurs as a natural process of 
aging [133], an intense heightened dark melanized pigment (hyperpigmentation) appears in the SNc 
preceding not only neuronal degeneration but also -synuclein aggregation, inflammation, oxidative Int. J. Mol. Sci. 2011, 12                 
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stress, apoptosis, Lewy body formation, depletion of GSH, functional loss of DAT and the loss of 
tyrosine hydroxylase positive neurons [10,128,134,135]. With PD, a biphasic but final loss of NM 
occurs gradually due to massive oxidation, cell death and release of NM from dying cells [136]. The 
loss of melanized nigral DAergic neurons is evident in PD brains (Right) when compared to healthy 
controls (Left) as shown in Figure 3 and is a major part of the pathology [137]. Ultimately, the loss of 
NM renders failure of its natural protective function, which is to sequester iron, free radicals and  
toxic quinones [138]. 
Figure 3. Melanized dopaminergic neurons of the substantia nigra from post mortem 
human brain. Brain sections taken through the mid- brain of a normal (left) and a 
Parkinson’s disease patient (right). The Parkinson’s diseased hemisphere on the right 
shows a loss of the melanized neurons in the substantia nigra in the ventral midbrain [137]. 
 
 
The generation of DA oxidative toxins also includes enzymatic conversion of dopaminochrome to 
5,6,-dihydroxyindole by DT diaphorase, the free radical initiated conversion of o-hydroquinones 
(protective) to o-semiquinones (toxic) [132] and transglutaminases which incorporate sulfur amino 
acids into DA-cysteine conjugate toxic precursors to neuromelanin [139]. And, recent studies suggest 
that transglutaminase inhibitors could be useful to prevent cross-linking reactions that lead to 
neurodegenerative aggregated proteins [140]. Animal models deficient in enzymes capable of 
catalytically oxidizing DA to DA-quinone (i.e., absent of PLA2 COX2), show a resistance to DAergic 
neurotoxicity after administration of MPTP. This is also corroborated where knockout models for 
SOD/GSH Px show extensive damage with MPTP [140–144], and protective effects are observed with 
COX/PLA2 inhibitors [145–148]. 
2.3.2. Non Enzymatic Oxidation of DA, 6-OHDA, Release of Iron & Oxidative Stress 
A second route for DA oxidation is non-enzymatically by reactive oxygen species (ROS) and metals 
(Fe
2+, Cu
2+, and Mn
2+) [149,150]. The autoxidation of DA can render formation of 6-OHDA (a potent 
neurotoxin) and O2
−. If superoxide reacts with nitric oxide (NO) the formation of ONOO
− is evident. 
Peroxynitrite in turn can cyclically re-oxidize DA, deplete available reduced glutathione/ascorbate 
(vitamin C), incur a substantial loss of endogenous GSH-peroxidase and destroy the natural ability of 
GSH to act as an antioxidant [129,151]. While PD patients display depletion of GSH within the   
SNc [152], the reduction of GSH (i.e., γ-glutamylcysteine synthetase inhibitor) in experimental models 
also renders the SNc vulnerable to the toxic effects of MPTP and 6-OHDA [8]. For this reason, thiol Int. J. Mol. Sci. 2011, 12                 
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based dietary antioxidants could be considered for clinical trials, as some have reported they prevent 
MPTP induced toxicity in mice [57,153], attenuate pathological effects of 6-OHDA, ONOO
− and 
block the formation of DA o-semiquinone neurotoxic radicals [154].  
Once 6-OHDA is formed, its presence can trigger neurodegeneration through reduction of striatal 
zinc and metallothione (otherwise antioxidant/metal detoxification agents) and initiate selective release 
of free iron from ferritin, where pro-oxidant effects predominate [152,155–160]. This could be perilous 
given the already high concentrations of iron dispersed throughout the substantia nigra, globus pallidus, 
red nucleus and locus cerulus [161–163]. Heightened free iron deposits are found in the vicinity of 
neurodegenerative regions, located in microglia, astrocytes and oligodendrocytes in conjunction with a 
rise in heme oxygenase (HO-1) (an enzyme which yields free Fe
2+ iron from heme) and disappearance 
of NM (loss of high affinity binding polymer for Fe
2+) [164–168]. In PD patients, iron deposition near 
degenerating neurons [169], could be intensified by hereditary mutations in iron regulatory binding 
proteins [170,171], iron storage/transport proteins such as ferritin (L/H subunits stabilization: 
storage/ferroxidase mediated uptake and utilization), caeruloplasmin, iron regulatory protein 2, 
lactoferrin/melanotransferrin receptors or the divalent metal transporter-1 [172,173]. Further, the 
accumulation of iron could be heightened by HO-1 which is significantly expressed in SNc 
dopaminergic neurons, the nigral neuropil, reactive astrocytes and Lewy bodies [174].  
To summarize, the dynamics of PD pathogenesis is believed to evolve in part from mitochondrial 
energy failure, and through a series of events—DA oxidation can perpetuate a cyclical generation of 
DAergic toxins and precipitate high levels of free iron released throughout the basal ganglia. These 
events initiate a forward cycle of self-perpetuated DA oxidation, loss of NM and Fe
2+ mediated 
damage which can indirectly fuel this loop by additional damage to the 26S proteasome prompting 
accelerated -synuclein protein aggregation [175] or production of OH radicals which can oxidize 
lipids/proteins and DNA [8]. This degenerative cascade could be worsened by genetic mutations in 
iron transport proteins such as divalent metal transporter 1 (DMT1/natural resistance associated 
macrophage protein 2/solute carrier family 11, member 2) as noted in the SN of PD patients [176].  
In Section 3, we discuss nutraceuticals that could impact each of these processes, in particular 
focusing on the important role that iron may play in PD pathology [177–179], the removal of which 
with iron chelators (i.e., EGCG, VK-28, clioquincol) is protective in a number of experimental   
models [40,178,179]. We also discuss the importance of using nutrient based combinations that contain 
chelators as just one module, since equally destructive forces are contributed by energy compromise, 
DA oxidation, concentration of free Fe
2+ and the subsequent down stream metal catalyzed aggregation 
of insoluble proteins [180]. 
2.3.3. Enzymatic DA Oxidation by MAO-DA Aldehydes & H2O2  
The third major route for oxidation of DA is through routine deamination by MAO A or B.   
MAO activity increases with the natural process of aging and can yield toxic products   
such as hydrogen peroxide (H2O2), ammonia, aldehydes, reactive oxygen species [180–182],   
3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde. The latter two have been 
reported to condense with H2O2 to form neurotoxic OH radicals [183,184]. And, in catecholamine 
neurons, DA can directly react with H2O2 leading to formation of 6-OHDA (neurotoxin) or   Int. J. Mol. Sci. 2011, 12                 
 
 
516
further condense with acetaldehyde to produce toxic endogenous precursors such as   
1,2,3,4-tetrahydroisoquinoline, 1,2,3,4-tetrahydro-β-carboline and R-salsolinol which are then subject 
to methylation [185–190] by either nicotinamide/salsolinol or phenylethanolamine   
N-methyltransferases forming toxic N-methylated pyridines with structure similar to   
MPTP/MPP
+ [191,186,187,191].  
2.4. Excitotoxicity  
Mitochondrial energy dysfunction not only leads to collapse of DAergic function, but also 
instability of neurons to maintain voltage at the plasma membrane. Depolarization can cause   
over-activation of NMDA receptors throughout the brain, where glycine binds to NR1 and glutamate 
to the NR2 initiating fast inward Ca
2+ currents to the cytoplasm. The general theory of excitotoxicity 
has remained consistent throughout the years and has been described to involve depolarization of the 
plasma membrane creating excitability in part due to (1) release of Mg
+ as a voltage dependent   
N-methyl-D-aspartate (NMDA) block at presynaptic receptors (2) greater susceptibility to excitatory 
postsynaptic inward Ca
2+ currents in response to glutamate activation on ionotropic 
NMDA/AMPA/kainate receptors and (3) a loss of inhibitory GABA metabotropic-inward ion currents 
upon receptor activation. 
Mitochondrial toxins such as rotenone can worsen the heightened amplitude of inward ionic 
currents, effects known to be are reversible by addition of ATP [192]. In terms of circuitry, a deficit of 
magnesium (Mg) or ATP can lead to failed regulatory control of intracellular Ca
2+ systems through 
changes  not only at the NMDA receptor but also intracellularly through influences on inositol   
1,4,5-trisphosphate and ryanodine receptors [193,194]. In vivo, studies show that dietary deficiency of 
Mg lowers NMDA receptor activation threshold and correlates to the overexcitability of glutaminergic 
neurons [195]. In Section 3, we discuss the importance of dietary Mg, in this and many other processes 
involved with PD pathology. 
In PD, the over-excitability of the NMDA receptor may contribute to neurodegeneration because 
Ca
2+ activation of neuronal nNOS can lead to nitrosative stress—a known primary elemental monomer 
modification leading to toxic mis-folded and aggregated proteins [196,197]. In reciprocal fashion, the 
accumulation of -synuclein can stimulate nNOS, caspase-3 and initiate poly(ADP-ribose) polymerase 
(PARP-1) cleavage, all events which contribute toward neurotoxicity [198]. The toxic effects of   
-synuclein on activation of nNOS are corroborated by studies that demonstrate that effects are 
blocked in the presence of NMDA receptor antagonists such as MK-801 and APV [199].  
In addition, mitochondrial toxicity (i.e., MPTP) also leads to accumulation of glutamate in the SNc 
to an extent parallel to degenerative lesion [200]. The rise in glutamate stimulates increase influx of 
Ca
2+ calpain activation in the cytosolic compartment, and these toxic effects are reversed by 
administration of NMDA antagonists, calpain inhibitors or antioxidants [201–203]. While the role of 
the NMDA receptor as it relates to PD is continually debated, it is noteworthy to mention that there is 
a very delicate balance between preventing over-activation or under-activation of glutaminergic 
receptors. The function of glutamate in neurotransmission is required for synaptic plasticity. And, as 
such, some studies also show that NMDA agonists such as D-cycloserine are protective against MPTP Int. J. Mol. Sci. 2011, 12                 
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induced DAergic degeneration and microglial activation in the brain [204]. So clearly, this topic is 
very complex. 
2.5. Inflammation 
Both dying neurons and aggregated -synuclein can trigger local gliosis, microglial activation,  
T cell infiltration and elevated expression/release of immunological participants [205]. These include 
major histocompatibility antigens, adhesion molecules, COX-2, IL-1b, IL-2, IL-4, IL-6, TNF-alpha, 
prostaglandins, glutamate, ROS, iNOS, MPO, NO and O2
− the latter two of which can react forming 
the neurotoxic molecule ONOO
− [205–215]. Many of the inflammatory indicators are found in   
post-mortem tissue obtained form PD patients, particularly in regions of the SNc, striatum, LC and 
spinal fluid [216]. Major regulators of this response involve tyrosine kinase, phosphatidylinositiol  
3-kinase (PI3K)/Akt, and the mitogen activated protein kinase (MAPK) signaling pathways such as c-Jun 
NH2-terminal Kinase (JNK), extracellular signal-regulated kinases (ERK) ½ p38 MAPK [46,217–222]. 
MAPK’s are evoked by cytokines or inflammatory stimuli, regulated by protein kinase A/cAMP and 
ultimately direct gene transcription by phosphorylating nuclear factor-kappa B (NF-κB) [223–226]. 
PET imaging using PK11195, [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline 
carboxamide] show active microglia occurring around neurodegenerative lesions in idiopathic PD 
patients vs. controls [227]. 
Figure 4. In the PD patient (A and B), binding is increased in the basal ganglia, pons and 
frontal regions, while the healthy control person (C and D) only shows constitutive 
[11C]  (R)-PK11195 binding in the thalamus and pons. The color bar denotes binding 
potential values from 0 to 1 [227]. 
 
 
The use of anti-inflammatory agents may attenuate DAergic damage and antagonize global effects 
through targeting a number of signaling routes such as MAPKs, NF-kappaB activation/nuclear 
translocation or its association with the CREB-binding protein, IkappaB kinase (IKK), activating 
protein-1 (AP-1) and/or preventing IkappaB degradation or phosphorylation of c-jun N-terminal kinase 
(JNK) [228–231]. Substances that can inhibit any one of these mechanistic controls should block  
pro-inflammatory processes and antagonize the formation of iNOS, COX-2, PGE (2) or HO-1, thereby Int. J. Mol. Sci. 2011, 12                 
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preventing DAergic loss induced by MPTP [232–237]. The co-expression of iNOS and COX-2 could 
be detrimental because the product formed by NO and O2
− (ONOO
−) plays a highly relevant role in the 
pathological processes involved with PD. Removal of one or both of O2
− and NO/ONOO can prevent 
the deleterious effects of PD model toxins, as reported in transgenic mice deficient in iNOS, nNOS, 
NADPH oxidase or with overexpression of Mn/SOD conferring resistance to the toxicological   
effects of MPTP or intrastriatal injection of 6-OHDA [238–243]. Likewise, administration   
of specific nNOS/iNOS inhibitors or SOD mimetics can protect against the neurotoxicity of   
MPTP [33,42,244–246]. In the next section, we review nutraceuticals with multi-capabilities on   
anti-inflammatory signaling processes. 
3. Nutraceuticals  
3.1. Energy—Biochemistry and Metabolism 
Considering the cascade of degeneration in PD as it involves mutations affecting protein 
degradation and folding, inadequate energy production in the SNc, DAergic malfunction, degenerative 
oxidative damage, excitotoxicity and inflammation, the question remains if any nutraceuticals or 
dietary practices as a lifetime habit can prevent or block one or more of these pathways and as a result 
slow the progression of PD. The next section provides a review of previous studies and future 
directives based on mechanisms as discussed above.  
3.1.1. Pyruvic Acid 
To overcome the loss of ATP, due to single or multiple hits directed at the mitochondria within 
neurons of the SNc, the first question to arise is to elucidate if it is possible to enhance anaerobic 
capability of the human brain, when physiological control over glucose concentrations are highly 
regulated. In order to optimize anaerobic glycolysis within the brain, dietary compounds must pass 
through the blood brain barrier (BBB) and likely work to promote key glycolytic regulators of 
substrate level phosphorylation including phosphoglycerate kinase, pyruvate kinase or lactic acid 
dehydrogenase (LDH), which would propel production of ATP [74,247,248]. Nutrient offsets 
associated with these enzymes are clearly altered during CNS neurological injury as evidenced by 
significant elevation in the ratios of lactate/pyruvate, NAD
+/NADH and NADP
+/NADPH [249]. These 
nutrient offsets suggest “metabolic stress” and accelerated use of nicotinamide reducing equivalents to 
drive survival processes to produce ATP through anaerobic shifts, in particular ischemia. The 
anaerobic process is fueled by the metabolite pyruvate (PY), which is a substrate for the LDH enzyme. 
Our investigations of the molecule PY, have indicated it to be the most powerful antioxidant of the 
glycolytic metabolites, also having capability of protect neuroblastoma against MPP
+/6-OHDA and 
H2O2 toxicities in vitro [247–250]. It is possible that oral administration of PY could be capable of 
entering the brain, serving as a substrate for glycolysis, the Krebs cycle and the GABA shunt [251] and 
for this reason its use has been effective in preventing neurological damage associated with ischemic 
stroke [252]. Recently, other attributes of PY include an ability to block NMDA excitotoxicity in 
hippocampal neurons [253]. Although future research will be required to corroborate this, it would 
seem logical to combine oral administration of pyruvate, w/Mg (a required cofactor for pyruvate Int. J. Mol. Sci. 2011, 12                 
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kinase) and niacin (precursor of reducing equivalents) which could help to restore nutrient offsets that 
occur due to accelerated anaerobic glycolysis in the CNS, when oxygen or mitochondrial function 
is insufficient. 
3.1.2. Niacin 
Furthermore, a deficiency of niacin is known to increase the risk for DAergic neurons to   
degenerate [191]. Likewise, the toxicity of MPTP is associated with a depletion of niacin, likely due to 
high demand for NAD
+ in several biochemical processes including glycolysis and apoptotic over 
activation of PARP-1 [254–256]. The administration of niacin has shown protective against MPTP 
induced SNc cell loss and striatal DA depletion in vivo, effects which are possibly due to preventing 
drop in ATP by fueling glycolysis and preventing PARP-I NAD
+ depletion [257–259]. Further 
upstream, PARP-1 is under regulatory control of tumor suppressor protein p53, a transcription factor 
that controls programmed cell death and cell cycle arrest. For this reason, it is not surprising that 
administration of either niacin, PARP-1/p53 inhibitors or PARP-1 knockout mice all show a resistance 
to MPTP mediated DAergic toxicity [256,257,260–262]. Therefore, the use of niacin as a therapeutic 
agent could be explored further, given its vast biochemical benefits including additional contribution 
to the pentose phosphate pathway, which regulates endogenous removal of H2O2 (a major contributing 
factor to PD pathology) through the GSH-Px system [191]. And, in our previous work, we have also 
found NADH to be a powerful antioxidant, alone capable of protecting against peroxide induced 
toxicity in neuroblastoma [247]. 
With regard to niacin, it is important to make note that a bit of controversy surrounds its use 
particularly as it relates to PD. Concern has been expressed that its administration could lead to 
synthesis of endogenous N-methylated nicotinamide, a compound with structural similarity to   
MPP
+ [263]. Nicotinamide N-methyltransferase (NNMT) is the enzyme that can readily convert 
pyridines to toxic substances very similar to the PD toxic metabolite MPP
+ [191]. While future 
research will be required to investigate these concerns, it may be possible to combine administration of 
niacin with natural compounds known to down regulate NNMT such as plant derived isoquinoline 
alkaloids, caffeine ± precursors (i.e., xanthosine—green tea or cocoa tea), which reportedly compete 
for methyl groups otherwise donated by s-adenosyl-L-methionine to drive NNMT enzyme   
activity [264–266]. The positive effects of caffeine are consistently reported as both administration of 
caffeine in animal models is therapeutic against MPTP and most importantly human epidemiological 
studies show that coffee consumption is associated with a decreased risk for developing PD [267,268]. 
As a side note, magnesium may also be a downregulator of NNMT [269]. 
3.1.3. Magnesium  
Dietary magnesium (Mg) has a vast role in integrated human metabolism and is critically involved 
with production/utilization of ATP in the human brain. A number of studies suggest that a dietary 
deficiency of Mg is associated with greater loss of DAergic neurons [270]. And. low Mg brain tissue 
concentrations are evident in human PD patients [271]. With regards to the review on the pathology of 
PD above, Mg plays an indispensable role in proper DA uptake and vesicular storage and   
transport [272]. Heightened levels of Mg can attenuate effects of Ca
2+ overload [273,274], augment the Int. J. Mol. Sci. 2011, 12                 
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function of VMAT2 for sequestration of DA and provide a voltage dependent non-competitive block 
of the NMDA receptor otherwise responsible for excitability of neurons [199,275,276]. Ample Mg
+ in 
the diet could be critical for PD patients, because of its diversity in energy related functions, energy 
storage processes (phosphocreatine), and its ability to thwart Ca
2+ mediated neurotoxicity [276,277]. 
Mg also plays a critical functional role in activation of CuZn-SOD, and could thereby attenuate 
formation of ONOO
−, involved with -synuclein aggregation [278]. As a note, oral administration of 
Mg could benefit when co-administered with vitamin B6 and vitamin D. both which assist to maximize 
its adsorption and utilization. 
3.1.4. B Vitamins and Regulation of Physiological Homocysteine 
Another role for vitamin B6 pertaining to the pathology of PD is its conjunction with vitamin B12 
and folate which regulate homocysteine by aiding its breakdown to methionine and tetrahydrofolate. 
These effects may attenuate neurotoxicity associated with hyperhomocysteinemia—a condition that is 
not only associated with PD pathology, but also the toxicity of MPTP in experimental models and as a 
side-effect of L-DOPA [279–281]. High levels of homocysteine could greater the severity of PD 
because it mediates toxicity by acting on NMDA receptors to precipitate oxidative stress, Ca
2+ 
overload and apoptosis [282]. Vitamin B6 could also help to antagonize the hyperhomocysteinemic 
effects of nicotinamide via enhanced methylation [279]. Folate is another critical nutrient, where 
deficiencies in human PD patients have been observed in association with greater levels of plasma 
homocysteine [283,284]. In experimental models, the effects of hyperhomocysteinemia are known to 
potentiate the neurotoxic effects of MPTP [285]. For this reason, folate, B12 and vitamin B6 could be 
combined with a nutraceutical such as betaine and/or serine, which reduce homocysteine levels 
through aiding in its regulatory conversion to methionine or cysteine, respectively [286,287]. Garlic is 
another natural compound which can prevent the build up of homocysteine given its ability to 
stimulate cystathionine β-synthase and inhibit N
5,N
10-methylenehydrofolate reductase [288]. Further 
research will be required to explore the combined use of these particular B-vitamins with some of 
these nutraceuticals as it relates to homocysteine accumulation and neurotoxicity in human PD. 
3.1.5. B Complex Vitamins, Riboflavin and Mitochondrial Disorders  
There is also rationale to substantiate use of B-Complex vitamins for PD patients, due to the critical 
role these nutrients play in glucose metabolism and mitochondrial respiration. Vitamin B2 derivatives 
such as flavin adenine dinucleotide (FAD)/flavin mononucleotide (FMN) regulate aerobic 
mitochondrial metabolism by mediating redox reactions through the electron transport chain [74,289]. 
Interestingly, the use of oral riboflavin supplements in humans can reverse clinical symptoms 
associated with mitochondrial myopathy/pathologies (involving complex I–II), where reduction of 
lactate and restored mitochondrial function are associated with clinical improvements [290–294]. And, 
use of coenzyme Q10 (which plays a role in complex I-II function) for treatment of PD has been of 
considerable interest, although clinical trials have not yet confirmed therapeutic effects [295,258]. The 
B-Complex vitamins such as thiamin (vitamin B1), lipoic acid, biotin, vitamin B6, B12 folate, and 
pantothenate work together symbiotically to drive pyruvate dehydrogenase complex, gluconeogenesis 
and blood, glucose, oxygen delivery to the brain. The B-complex vitamins each play a unique role  Int. J. Mol. Sci. 2011, 12                 
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of equal importance but work collectively to optimize mitochondrial function, in particular when 
challenged with toxins such as rotenone [296]. Clinical trials for multi-vitamin supplements therefore 
could be considered.  
3.1.6. Creatine, Chromium  
Nutraceuticals that optimize ATP storage reserves may further strengthen the capacity of energy 
requiring systems. Known disturbances in choline/creatine have been observed in PD patients [297], 
and creatine supplements have been shown to protect against MPP
+/MPTP, 6-OHDA and glucose 
deprivation [53,54,298]. However, preliminary studies in our lab have failed to show protective effects 
by creatine against MPTP induced DA degeneration in the mouse model, a topic under current 
investigation (unpublished). While creatine could be beneficial in augmenting ATP storage, chromium 
salts would be equally important in maintaining physiological glucose, glucose tolerance, insulin 
sensitivity [299] and glycemic functions [300]. Adequate chromium in the diet seems fitting given its 
role in optimizing systemic glucose metabolism, despite a lack of evidence to suggest chromium 
aberrations in cerebral spinal fluid of PD patients [301]. 
3.2. Plant Polyphenols—Attenuation of DA Oxidation 
The use of vitamins to support energy function could further be combined with plant derived 
polyphenolic compounds (PDPC) that specifically target downstream toxic effects as a direct result to 
the loss of ATP. These include collapse of DA trafficking, DA oxidation, generation of ROS, fenton 
reactions, DAergic neurotoxins, loss of NM and CNS glial inflammation. A number of food-based 
molecules have previously been reported in the literature as being effective in antagonizing specific 
events within these processes. 
3.2.1. Tyrosinase Inhibitors 
As stated previously, the initial oxidation of DA to DA-quinone, or from DA quinone to its toxic 
metabolites are believed to contribute toward DAergic degeneration. Although future research will be 
required to substantiate this, these processes could be blocked by nutraceuticals such as polyphenolic 
inhibitors of tyrosinase, COX, lipoxygenase, PLA2, xanthine oxidase or antioxidants/metal chelators.  
The first to review is tyrosinase/polyphenol oxidase (PPO) which is a copper requiring 
metalloenzyme that catalyzes formation of o-quinones. A heightened enzyme activity of tyrosinase 
could be associated with elevated risk for PD [302] and skin hyperpigmentation disorders [303] both 
which involve heightened oxidation of L-DOPA to form dopachrome [304,305]. These same processes 
are often researched in the field of food chemistry, due to food browning reactions occurring through 
PPO enzymes in vegetables such as potato or mushroom. Creatively, it has been proposed that such as 
model could serve practical for the investigation or screening of nutraceuticals against DA oxidation 
processes as it relates to PD [306]. Future research could be done to consider analysis of established 
nutraceuticals known to inhibit tyrosinase, some of which include the following: Int. J. Mol. Sci. 2011, 12                 
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Table 1. Tyrosinase Inhibitors. 
Tyrosinase Inhibitors  Reference 
Tetrahydroxychalcones, Butein   [307,308]  
Prenylated flavonoids, Sanggenon D   [309]  
Sophoraflavanone G, Kuraridin, Kurarinone, Norkurarinol  [310,311] 
Cinnamic acid, Aloin, Sophorcarpidine   [312,313] 
Glabrene/Licorice, licuraside, isoliquiritin and licochalcone   [314,315]  
Quercetin, Galangin,Morin, Fisetin, Luteolin, Apigenin,   [316] 
Esculetin   [317]  
Hexylresorcinol, Dodecylresorcinol   [318] 
Oxyresveratrol   [319]  
Gnetol   [320]  
(−)-Epigallocatechin-3-gallate, Hinokitiol (beta-thujaplicin), Kojic acid  [321,322]  
Reduced glutathione, cysteine, thiol compounds, ascorbic acid, acetic acid  [323–326] 
Dimethylsulfide [327]   
Phytic acid  [328]  
Tannic acid  [329] 
Nobiletin   [330] 
Kaempferol [331,332] 
Extract of hibiscus, carex pumila, and garcinia subelliptica  [333]  
Wine phenolics  [334]  
Green tea  [335]  
Procyanidins, Grape seed extract  [336,337] 
Gallic acid derivatives  [338] 
Safflower [339] 
Aisic acid  [340]  
Olive oil constituents  [341] 
3.2.2. COX Inhibitors 
Natural inhibitors of COX could also block the initial step of enzymatic DA oxidation to DA 
quinone through PGH2 synthase. A review of the literature shows a number of promising plant derived 
polyphenolic compounds (PDPCs) as effective COX inhibitors such as: 
Table 2. Cycloxygenase I/II Inhibitors. 
Cycloxygenase I/II Inhibitors  Reference 
Quercetin, Kampferol, Chrysin and Galangin  [342,343] 
Anthocyanins, Delphinidin, Cyanidin, Malvidin  [344,345] 
Galangin, Morin, Apigenin, Rutin, Catechin, EGCG, Quercetin, Chrysin, 
Flavones, Luteolin, Tectorigenin, Bilobetin, Nobiletin, Fisetin, Naringenin, 
Quercetin, Lonchocarpol, Tomentosanol and Wogonin 
[346–349]  
Quercetin, Quercetin 3-glucuronide, Quercetin 3'-sulfate 3'-methylquercetin  
3-glucuronide 
[350,351] 
Ursolic acid, Eugenol, Pyrogallol and Cinnamaldehyde  [352] 
Ipriflavone, Resveratrol, MSV-60, Amentoflavone, Ruscus extract  [353,354] Int. J. Mol. Sci. 2011, 12                 
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Table 2. Cont. 
Notoginseng Prenylated flavonoids, Morusin, Kuwanon C, Sanggenon, Kazinol, 
Kuraridin, Kurarinone, Sophoraflavanone G 
[355] 
Butein and 7,3',4'-trihydroxy flavone  [356] 
Coumarins, Bergapten  [357] 
Amentoflavone [358] 
Oroxylin A  [359] 
Caffeic acid Phenethyl Ester and Propolis  [360] 
3.2.3. Lipoxygenase Inhibitors  
PDPC’s that may be able to block the initial step of enzymatic DA oxidation to DA-quinone 
through inhibition of lipoxygenase (5-LOX, 12-LOX) and include the following: 
Table 3. Lipoxygenase Inhibitors. 
Lipoxygenase Inhibitors  Reference 
Luteolin, Baicalein, Fisetin, Quercetin, Eugenol, Curcumin, Cinnamaldehyde, 
Piperine, Capsaicin, Allyl sulfide, Oroxylin A, Wogonin 
[361–364] 
Morin, Galangin, Kaempherol, Taxifolin, EGCG, Esculetin, Propyl gallate  [365–367] 
Coumarin, 7-hydroxy-derivative, Fraxetin, Daphnetin, Coumarin derivatives  [368] 
Amentoflavone [369] 
Kuraridin, Sophoroflavonone G, Kenusanone A, Psoralidin  [370] 
3,5,6,7,3',4'-hexamethoxyflavone, Sinensetin, Nobiletin, Tangeretin, Rhamnetin 
Tetramethylscutellarein, 6,7,8,3',4'-heptamethoxyflavone, Hesperidin, Ferulic acid 
[371] 
Sophoraflavanone G, Quercetin, Kenusanone A  [372] 
Circiliol, Hypolatein, Sideritloflavone [373] 
Silymarin [374] 
Bean (Phaseolus vulgaris L.) hulls  [375] 
Cirsiliol, Hypolaetin, Hypolaetin-8-O-beta-D-glucoside, Gossypetin, Gossypin, 
Hibifolin, Leucocyanidol 
[376,377] 
Oroxylin A, Baicalein, Wogonin  [378] 
Procyanidins [379] 
Quercetin glycosides  [380] 
Entaureidin and 5,3'-dihydroxy-4'-methoxy-7-carbomethoxyflavonol  [381] 
 
3.2.4. Phospholipase A2 Inhibitors 
While PLA2 inhibitors attenuate DA oxidation reactions, they may serve dual function in PD 
pathology because they also block formation of arachidonic acid as a substrate for prostaglandins. PLA2 
inhibitors could be combined with administration of omega-3 fatty acids (i.e., canola/fish oil), thereby 
reducing PGE2 (a pro-inflammatory prostaglandin specifically associated with PD pathology) [377].  
Co-administration of vitamin E may enhance absorption of omega-3 fatty acids and prevent fatty acid 
oxidation. Future research could consider analysis of plant-derived compounds that are known to 
inhibit PLA2 in experimental models of SNc DAergic damage, some of which are known to include:  Int. J. Mol. Sci. 2011, 12                 
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Table 4. Phospholipase A2 Inhibitors. 
Phospholipase A2 Inhibitors  Reference 
Quercetin. Kaempferol,Myrecetin,Kaempferole-3-galactoside, Scutellarein, 
Ochnaflavone, Amentoflavone, Ginkgetin, Isoginkgetin, Morelloflavone, 
Bilobetin, Prenylated flavonoids 
[342] 
Ginkolide [378] 
Amentoflavone, Ginkgetin  [379] 
Fish oil, Evening primrose oil  [380,381] 
2',4',7-trimethoxyflavone [382] 
Nobiletin [383] 
Rosmarinic acid  [384] 
Omega-3 fatty acids  [385] 
3.2.5. Xanthine Oxidase Inhibitors 
The initial step of enzymatic DA oxidation to DA quinone could be attenuated by xanthine oxidase 
inhibitors, some of which are known to include the following: 
Table 5. Xanthine Oxidase Inhibitors. 
Xanthine Oxidase Inhibitors  Reference 
Skull Cap (Scutellaria baicalensis (SbE)), Grape seed proanthocyanidins  [386] 
Hesperitin, Theaflavin-3,3'-digallate, Cranberry juice  [387–389] 
Chrysin, Phloretin, Luteolin, Kaempferol, Quercetin, Myrecetin, Galagin, Apigenin, 
Morin, Isorhamnetin, Fisetin, Rutin 
[390–395] 
EGCG, 4-t-butylcatechol,Catechin,Fisetin,Luteolin,Raxifolin [395,396] 
Quercetin glycosides  [397] 
Apigenin, Quercetin, Isovitexin  [398] 
Hydroxyl or Methyl Chalcones (i.e., 3,3,4,4-tetrahydroxychalcone), Esculetin,  
4-methylumbelliferone 
[399] 
Propolis, Caffeic acid phenetyl ester, Chrysin, Galangin  [400,401] 
5,7,4'-Trihydroxy-6-methoxyflavone p-coumaric acid derivatives drupanin,  
4-acetyl-3,5-diprenylcinnamic acid, trans-ferulic acid O-hexan-3-onyl-ether 
[402] 
Baicalein, Wogonin, Baicalin  [403–405] 
Pycnogenol, Silymarin, Silybin, Silybin flavones, Purpurogallin  [406,407] 
Black Tea  [408] 
Procyanidins, Pygnogenol  [409–412] 
Anthocyanins, Cyanidin, Cyanidin 3-O-beta-D-glucoside [413] 
Myricetin Glycosides  [414] 
 
3.2.6. Xanthine Oxidase and Superoxide Scavengers 
Combined xanthine oxidase/superoxide scavengers may reduce oxidative stress, prevent formation 
of ONOO and attenuate the degenerative process, some of which are known to include: Int. J. Mol. Sci. 2011, 12                 
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Table 6. Xanthine Oxidase and Superoxide Scavengers. 
Xanthine Oxidase and Superoxide Scavengers  Reference 
EGCG, EGC, Pyrogallol, Catechin, Luteolin, Myrecetin, Rutin, Apigenin, Quercetin, 
Hesperitin, Naringenin, Biochanin, Retinol, Daidzein, Genestein, 4-t-butylcatechol, 
Taxifolin, Fisetin, Kaempferol, 5,7,4'-trihydroxy-6-methoxyflavone 
[395,402,415–417] 
Caffeic acid, Rosmarinic acid, Salvianolic acid, Sage  [418] 
Apigenin, Quercetin, Diosmin  [419] 
Green tea polyphenolics, Theaflavin, EGCG  [388,389,420,421] 
Scutellarin [422] 
Oligomeric proanthocyanidins, EGCG, Delphinidin, Myrecetin, Gallic acid, Caffeic 
acid, Fisetin, Quercetin, Catechin, Epicatechin 
[423] 
Galangin/Caffeic acid phenethyl ester, Propolis, Caffeic, Chlorogenic acid, Gallic acid  [401,424,425] 
Baicalein, Baicalin, Morin  [404,426,427] 
Uric acid  [428] 
Chrysoeriol ± glycoside  [429] 
Anacardiaceae spice  [430] 
Myrecetin, Fisetin, Quercetin  [431] 
3.3. Histidine, Quercetin and Zinc 
Other polyphenolic compounds that may block the initial step of enzymatic DA oxidation include 
substances which down regulate DT diaphorase or mono-oxygenases such as EGCG [432],   
flavones [433] baicalin, oroxylin-A glucoronides [434], quercetin [435] or histidine [436]. While we 
mention the protective properties of EGCG and quercetin on PD related processes throughout   
this review, noted effects of histidine may also include its ability to augment the uptake and   
transport of zinc into the brain, where zinc can counteract the pro-oxidant effects of iron [437],   
ischemia-reperfusion [438,439] or mitochondrial toxins such as MPP
+ [440]. See Section 3.8. 
3.4. N Acetyl Cysteine 
Thiol based compounds are believed to help slow non-enzymatic autoxidation of DA in the 
presence of ROS and metals (Fe
2+, Cu
2+, and Mn
2+) [149,150]. Autoxidation of DA to 6-OHDA 
(a potent neurotoxin) and O2
− can be lethal in the presence of NO, forming ONOO
−. Peroxynitrite can 
then re-oxidize DA and deplete available reduced glutathione and ascorbate [129,151]. Possible 
dietary counter intervention could include thiol antioxidants such as NAC which in experimental 
models blocks the autoxidation of DA, prevents MPTP induced toxicity in mice [57,153]   
attenuates pathological effects of 6-OHDA, ONOO
− and blocks the formation of DA o-semiquinone  
neurotoxic radicals [154].  
3.5. Hydrogen Peroxide Scavengers 
The third route of DA oxidation is through deamination by MAO A or B which yields H2O2, 
ammonia [180–182], 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde. The 
latter two condense with H2O2 to form OH radicals [183,184] and DA reacts with H2O2 leading to form 
6-OHDA or condenses with acetaldehyde to produce toxic precursors subject to methylation [185–190]. Int. J. Mol. Sci. 2011, 12                 
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Due to the importance of MAO activity and the initial condensation reaction between catecholamines 
and aldehydes that create precursors subject to methylation, future research could investigate 
therapeutic food based compounds that work as (1) MAO inhibitors (2) compounds that potentiate 
aldehyde dehydrogenase such as GSH, NAD
+ (3) down regulate nicotinate/phenylethanolamine   
N-methyltransferases such as caffeine or 4) scavenge H2O2.  
Removing hydrogen peroxide generated by MAO or DA autoxidation could be very beneficial in 
slowing the rate of progression in PD. Hydrogen peroxide, if present in high quantities can oxidize DA 
to 6-OHDA, which in turn can then react with 6-OHDA to propagate OH radicals, contributing to the 
formation of -synuclein-Fe aggregates and insoluble filaments [35,441]. The generation of H2O2 in 
DAergic neurons initiates multiple degenerative processes such as improper degradation of oxidized 
proteins through the ubiquitin proteasome pathway, formation of dopachrome and toxic DA   
quinones [132,442,443]. The role for peroxide in PD pathogenesis is evidenced by the fact that its 
removal via potentiation of catalase/SOD prevents injury in MPTP models of injury. Transgenic mice 
that over express cytosolic CuZn-SO/GSH-Px or applied administration of SOD/catalase mimetics 
(which both dismutase O2
−, and convert subsequent H2O2 to water) provide protection against MPTP, 
paraquat and 6-OHDA in vivo models of injury [33,243,444–446]. In contrast, reduction in   
GSH-Px/CuZn SOD (i.e., knockout mice) leaves the SNc area vulnerable to oxidative stress and 
MPTP injury [143,447]. For these reasons, beneficial nutritional substances could include those that 
upregulate endogenous glutathione peroxidase and/or catalase, such as NAC, GSH, selenium, 
vitamin E, NADPH and curcumin [448]. Co-administration of niacin (which provides NADPH to drive 
GSH-Px) along with substances that augment function of GSH-PX could provide synergy in protecting 
SNc neurons from oxidative stress [57,153]. Other useful nutritional substances could include those 
that aid in SOD such as methionine, manganese, copper, zinc and propolis [449] and H2O2 scavengers 
which are known to include the following: 
Table 7. Peroxide Scavengers. 
Peroxide Scavengers  Reference 
Acacetin, Dihydrorobinetin, Fisetin, Isorhamnetin, Robinetin, Myricitrin, Hyperoside  [450] 
Resveratrol, Catechin, Gallocatechin  [451,452] 
Pygnogenol, Pyrogallol, Gallic acid, Anthocyanidins [452,453] 
Gallic acid, Trolox, Kaempferol  [454] 
Vanillic/Caffeic acids  [450] 
Baicalein [448] 
Hydroxytyrosol   [442] 
3.6. Iron Chelators  
6-OHDA generated during DA oxidation, reduces metallothione and causes release of free iron 
from ferritin [152,155,160]. Natural substances that antagonize 6-OHDA toxicity such as NAC, GSH, 
cysteine, pyruvic acid, [455] and zingerone [456] or are integral constituents of metallothioneine such 
as serine, lysine and cysteine [155] could be further researched. The accumulation of free iron is 
deleterious because it is associated with degenerating SNc neurons, surrounding glial cells and found 
after administration of MPTP/6-OHDA in animals [164–169]. Faulty iron homeostasis in the basal Int. J. Mol. Sci. 2011, 12                 
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ganglia could lead to a number of oxidative reactions, the acceleration of -synuclein protein 
aggregation [175] and formation of OH radicals which can damage neuronal lipid/protein and 
DNA [8]. It is reported that the use of iron chelators protect against MPTP and 6-OHDA models of PD 
toxicity [40,178,179]. A number of natural substances are capable of reducing/chelating complex iron 
including the following: 
Table 8. Iron Reducing/Chelating Compounds. 
Iron Reducing/Chelating Compounds  Reference 
Rutin, Morin, Rosemary, Sage, Oregano  [457] 
Phytic acid, Brown rice bran, Tannic acid  [449] 
Apigenin, Diosmin, Phloretin, Fisetin, Taxifolin, Naringenin  [458] 
Quercetin, Rutin, Myrecetin, Luteolin, Epicatechin Caffeic acid, Catechin, 
Kaempferol, Naringenin, Baicilein 
[459–464] 
Theaflavin, Theaflavin Digallate  [455,465,466] 
Vitamin E, Zinc  [467] 
Gallic Acid  [468] 
Silymarin, Silybin  [469] 
Rutin [470] 
3.7. Heme Oxygenase Inhibitors 
The accumulation of iron can also occur due to overactivity of the HO-1 enzyme, which can 
convert heme to free Fe
2+, and carbon monoxide, this also being significantly expressed in SNc 
dopaminergic neurons, the nigral neuropil, surrounding reactive astrocytes and Lewy bodies [174]. Up 
regulation of HO-1 occurs as a natural response to oxidative stress and correlates to iron deposition in 
the nigral area with degenerative SNc lesions. For this reason, potentially helpful nutritional 
substances may include those that can inhibit HO-1 directly such as cysteine, resevatrol, vitamin C, 
sulfur compounds (i.e., NAC, GSH) [471], apigenin [472], quercetin and kaempferol [473]. 
3.8. Zinc and Selenium 
While reactive iron contributes to the degeneration in SNc, the administration of zinc (Zn) and 
selenium (Se) could strengthen combination nutraceutical strategies [474–476]. Dietary intake of Se, 
Zn are required for the function/expression of endogenous antioxidant enzymes and ample amounts 
can attenuate iron-induced, MPTP and 6-OHDA induced DAergic degeneration [150,475,477]. 
Furthermore, chronic inflammation can bring about a Zn deficiency due to the use of Zn-dependent 
transcription factors that regulate DNA/nucleic acid synthesis in response to cytokine activation in 
immunocompetant cells (i.e., hypozincemia) [478,479]. A Zn deficiency can also evoke a shift in the 
ratio of Cu/Zn rending less than normal function of the CuZn SOD, turning it from an antioxidant to a 
pro-oxidant enzyme [479]. A requirement for zinc in the body could be justified with PD patients, 
since Zn mediates (a) downregulation of glutamate release, inhibition of NMDA/mGlu-R receptors, 
protection against NMDA neurotoxicity (b) renders a positive modulation on GABA release 
(c)  stimulates endogenous antioxidant enzymes and nerve growth factors (d) inhibits nNOS, 
endonucleases, pro-apoptotic cascades (e) augments synaptic plasticity and (f) is known to prevent age 
related deterioration of learning and memory [437].  Int. J. Mol. Sci. 2011, 12                 
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Both zinc and selenium contribute to anti-inflammatory effects through downregulation of MAPK 
p38, JNK and NF-κB DNA binding/AP-1 c Jun activation, where the therapeutic effects of Se also 
involve a rise in glutathione peroxidase/reduction of lipid peroxidation, increased glucose uptake, ATP 
production through glycolysis and an anti-apoptotic effects [474,480].  
3.9. Anti-Inflammatory Nutraceuticals 
The CNS inflammatory response is under the ultimate control of kinases such as tyrosine 
kinase [217], PI3K/Akt, and mitogen activated protein kinase signaling pathways such as JNK, ERK ½ 
p38 MAPK [46,218–222]. The topic of inflammatory is far too large for this review and therefore is 
summarized as follows. Briefly, MAPK’s are evoked by cytokines or inflammatory stimuli, regulated 
by protein kinase A/cAMP and ultimately control gene transcription by phosphorylating NF-κB which 
then binds to the promoter region of genes to initiate transcription for a range of pro-inflammatory 
proteins [223–226]. Anti-inflammatory agents can antagonize global effects through targeting a 
number of these signaling routes such as MAPKs, NF-κB activation/nuclear translocation or its 
association with the CREB-binding protein, IkappaB kinase (IKK), activating protein-1 (AP-1) and/or 
preventing IkappaB degradation or phosphorylation of JNK [228–231]. In brief summary, natural 
substances that may provide protection include those that can inactivate phosphorylated MAPK’s such 
as ERK ½ kinase, p38 MAPK, JNK, inhibit IkappaB kinase, IkappaB degradation, NF-κB, AP-1 
activation, antagonize COX-2/PGE2/iNOS and reduce expression of TNF-alpha and other   
pro-inflammatory proteins in immuno-competent cells some of which are listed as follows:  
Table 9. MAPK/NF-κB/iNOS/COX-2 (−). 
MAPK/NF-κB/iNOS/COX-2 (−) Reference 
Selenium, Zinc  [429,435] 
Chrysin, Quercetin, Galangin, Propolis or its derivatives  [481–486] 
Apigenin [487,488] 
Luteolin [487,489,490] 
Diosmetin, 3-hydroxyflavone, Pillion,4’,7’-dihydroxyflavone, Ayanin, Luteolin, 
Tectochrysin, 3’,4’-dihydroxyflavone, Tamarixetin, Genestein, Kaempferol, 
Izalpinin, Ombuine, Biochanin, Tectorigenin, Daidzein, 7-hydroxyflavone, 
Rhamnetin, flavone, EGCG, Mearnsetin, Liquiritigenin, Myrecetin 
[491] 
Hydroxychalcones [228,492,493] 
EGCG/Green tea  [494–496] 
Butein [497] 
Anthocyanins [344,498] 
5,6,3’,5’-tetramethoxy 7,4’-hydroxyflavone, Artemisia Absinthium, Wormwood, 
Blackwalnut 
[235] 
Scutellarin [499] 
Isovitexin [500] 
Naringin, Hesperitin and Naringenin [501–503] 
Baicalein [504,505] 
Silibinin, Silymarin  [225,506,507] 
Amentoflavone [508] 
Licorice [509] 
Wogonin [510] 
Curcumin, Luteolin, Wognonin, Kaempferol, Nobiletin, Bilobetin  [342] Int. J. Mol. Sci. 2011, 12                 
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Additionally, phosphodiesterase (PDE) inhibitors, in particular PDE 1 and IV through altering 
cAMP can downregulate iNOS [511] and protect against MPTP toxicity [512]. Food based compounds 
known to inhibit PDE include the following: 
Table 10. Phosphodiesterase Inhibitors. 
Phosphodiesterase Inhibitors  Reference 
Butein [513] 
Cirsimarin [514] 
Grape Skins, Anthocyanin, Malvidin  [515] 
Diosmetin, Luteolin, Apigenin, Quercetin, Myrecetin  [516] 
(+)-Catechin, Caffeic acid  [517] 
Gingko Biloba  [518] 
Biochanin A, Tyrphostin, Diadzein  [519] 
Theophylline [520] 
Amentoflavone, Bilobetin, Sequoiaflavone, Ginkgetin, Isoginkgetin  [521] 
Scutellarein, Phloretin, Naringenin  [522,523] 
3.10. Toxic Protein Aggregates 
In this section we briefly discuss a potential for targeted nutraceutical therapies which would 
prevent accumulation of α-synuclein, augment the ubiquinone-proteasome system (UPS) or inhibit 
mammalian target of rapamycin (mTOR) signaling to upregulate autophagy, which may in the long 
term slow the progression of this disease.  
3.10.1. Nutraceuticals—Reduction of aggregated α-SYNUCLEIN (PARK1) 
In brief, the kinetics of α-synuclein aggregation involves a number of progressive stages some of 
which could be altered by nutraceuticals. A higher propensity for α-synuclein aggregation can occur 
due to missense mutations (A30P, A53T, E46K) in human PD [524]. The general kinetics of 
aggregation involves three stages: (1) a protein monomer must undergo a modification; (2) modified 
monomers can then readily interact with each other to form small aggregates and (3) aggregates after 
reaching a certain size, referred to as a “nucleus”, can undergo irreversible rapid volume expansion 
called elongation which result in the formation of fibrils, then taking up residence as toxic entities in 
neurons and Lewy bodies. The initial protein modifications can occur due to phosphorylation of   
α-Synuclein at Ser 129 (p-Ser 129), nitration at tyrosine residues and C-terminal truncation- all of 
which can lead to nucleation where aggregation becomes probable [525,526]. The initial protein 
modification stage can also occur due to neurotoxic insults including but not limited to DA oxidative 
products, NO, ROS and high concentration of metals [527–529]. In turn, α-synuclein can directly 
initiate increased membrane ion permeability, vesicle leakage of DA and decreased mitochondrial 
respiration [530,531], which in turn can generate compounds that lead to α-synuclein modification. In 
essence, α-synuclein can lead to toxicity, and neurotoxicity can lead to α-synuclein aggregation.  
In this review, we have covered information on nutraceuticals that indirectly attenuate events 
known to evoke the initial stages of propagative α-synuclein misfolding, such as iNOS, nNOS, DA 
oxidative products and the enzyme pathways by which DA quinones are produced (Sections 3.1–3.9). Int. J. Mol. Sci. 2011, 12                 
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In addition, nutraceuticals that inhibit enzymes that otherwise phosphorylate α-synuclein such as   
polo-like kinases (i.e., thymoquinone–black cumin) [532], casein kinase II (i.e., ellagic acid) [533,534], 
Gprk2GRK2/5 [535] or proteases such as calpains, calcium-dependent non-lysosomal cysteine 
proteases may prevent a tendency for α-synuclein to aggregate or result in truncated toxins of   
α-synuclein. The use of any nutri-therapy which can prevent likelihood of aggregation, should lessen 
cell burden of accumulated insoluble proteins which otherwise has affinity for lipids, presynaptic 
vesicles, membranes and can cause considerable damage to organelles including mitochondria [536]. 
3.10.2. (Parkin) E3 ubiquitin ligase and Proteosomal Dysfunction 
Once α-synuclein aggregates are formed, a second vulnerability for continued accumulation would 
be improper recognition and ubiquitination of specific target proteins for degradation by the 
proteasome. This can occur in part due to genetic defects in parkin-E3 ubiquitin ligase or its associate 
SCF complex (Skp1-Cullin-F-box protein complex) [537,538]. While nutritional constituents may not 
be able to halt faulty processes in ubiquitination, it may be possible to optimize the function of the 
proteasomal complex with dietary agents.  
The proteasomal complex consists of a 20S proteolytic core with two 19S regulatory caps, 
responsible for recognition, proteolysis, unfolding and transport of proteins into the core lumen for 
processing. Inhibiting the function of the proteasome with lactacystin, PSI or MG-132 can effectively 
mimic PD pathology including selective SNc degeneration, α-synuclein positive inclusion like 
granules and activation of glial cells [539,540]. Nutraceutical substances such as iron chelators can 
protect against the adverse effects of such proteasomal inhibitors with capability to prevent   
lactacystin-induced DA neurodegeneration in vivo [541]. These protective effects are likely because 
the proteasome can also be adversely affected or inhibited by DA oxidative metabolites, DA quinones 
or ROS, effects that are also blocked by antioxidants such as GSH, ascorbic acid, vitamin E, SOD or 
catalase [542]. In this aspect nutraceuticals could serve useful to protect against further insult to an 
already vulnerable proteosomal complex, not only due to mutations in parkin, but also due to lack of 
endogenous proteasome activator PA28 expression in the SNc, concomitant to reduced function of  
-subunit of the 20S proteasome in the SNc of sporadic PD patients [543,544]. 
3.10.3. Nutraceuticals, Autophagy and mTOR signaling  
A second degradation route for eliminating α-synuclein aggregates and malfunctional mitochondria 
is through the process of autophagy. The removal of depolarized damaged mitochondria is mediated 
through a process called mitochondrial fission which is regulated by membrane constriction through 
dynamin-related protein (Drp1) mitochondrial fission 1 and GTP hydrolysis [545] in preparation for 
clearance through autolysosomes. Notable mutations in PINK1 can adversely affect this process,   
by preventing both Drp1-dependent fragmentation and phosphorylation/relocation of Parkin   
to mitochondria where it then fails to catalyze mitochondrial ubiquitination, recruitment of   
ubiquitin-binding autophagic components, HDAC6 and p62, and subsequent mitochondrial   
clearance [546]. Together, genetic mutations in both PINK1 and Parkin lead not only to failure of 
mitochondria, but also a lack of mitochondrial quality control for proper degradation of mitochondria 
that are no longer functional. While nutritional constituents may not be able to reverse protein defects Int. J. Mol. Sci. 2011, 12                 
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associated with function of Park and PINK1 mutations, dietary factors can largely influence and 
activate autophagy-lysosomal function.  
Autophagy is described as the means by which cells degrade oxidized and damaged membranes, 
organelles and mis-folded proteins. This process is initiated by formation of a phagophore which 
expands and engulfs portions of the cytoplasm then forming a autophagosome [547]. The initiation 
stages of autophagosome formation is under control of signaling by class III phosphoinositide 3-kinase 
and Atg 6 (Beclin-1), which regulates phosphorylation of microtubule-associated protein 1 light chain 
3LC3 [548]. These phosphorylated LC3 marked vesicles are then trafficked along microtubules in a 
dynein reliant fashion and eventually fuse with lysosomes (autolysosomes), where contents are 
degraded by acidic lysosomal hydrolases. Lysosomes can also reach out on their own in a process 
called microautophagy where they directly engulf cytoplasm by invagination or septation. And, once 
inside the lysosome, cathepsin D becomes the main lysosomal enzyme involved in the degradation of 
α-synuclein [549]. 
The process of UPS and the autophagy-lysosomal systems are under direct control of mammalian 
target of rapamycin (mTOR) signaling. Stimuli that lead to upregulation of mTOR serve to block 
autophagy-lysosomal function and its contribution toward accumulated oxidized and damaged 
organelles/proteins. Signals that upregulate mTOR include those registering as high nutrient energy 
status signals, such as glucose, insulin, a high ratio of ATP/AMP ratio, leucine, oxidative stress [550], 
arginine [551] and high levels of amino acids [552]. The rise in mTOR and reduction in the   
autophagy-lysosome pathway can be chemically induced by 3-methyladenine or chloroquine, effects 
which lead to accumulation of Ser-129-phosphorylated α-synuclein [553]. This is opposite to the 
effects of rapamycin which through inhibition of mTOR activate clearance of aggregate-prone proteins, 
including α-synuclein as well as faulty mitochondria and prevent the toxic effects of proteosomal 
inhibitors on DAergic systems [554]. A number of substances in the diet are known to upregulate 
autophagy lysosomal function by downregulation of mTOR, some of which include resveratrol, 
spermidine, curcumin, piperine, caffeine, epigallocatechin gallate, garlic, S-allylcysteine [555–557], 
anthocyanins [558], selenium [559], eicosapentaenoic acid and lycopene [560]. Also, it is likely that 
nutraceuticals that could selectively inhibit IMPase, IP3, adenylate cyclase [561] or Akt signaling may 
downregulate mTOR and induce autophagosomal clearance [562]. 
4. Conclusion 
In conclusion, this review provides information on nutritional biochemistry as it relates to 
pathological processes inherent to PD. PD pathology involves both regional and systemic nutrient 
offsets that are largely related to heightened anaerobic glycolysis, homocysteine metabolism, faulty 
aerobic energy metabolism, metabolic stress, iron deposition and catecholamine mediated oxidative 
stress. These offsets could be aggravated by blood -tissue nutrient deficiencies as commonly reported 
in human PD patients or the process of aging itself, both which could exacerbate protein   
mis-folding/aggregation, disruption of proteasomal processes or losses in DAergic neurotransmission. 
Future research will be needed to investigate a strategic means to employ combined nutraceuticals that 
work effectively and collectively to alter metabolism or pathological processes in such a way as to Int. J. Mol. Sci. 2011, 12                 
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slow the progression of PD in humans. Any therapeutic strategy that can effectively do so, will afford 
extended quality of life to human PD patients. 
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